Article Information
- Received April 16, 2021
- Accepted April 20, 2021
- Published online April 27, 2021.
Author Information
- Akihito Kuboki1,2,
- Shu Kikuta3,
- Nobuyoshi Otori1,
- Hiromi Kojima1,
- Ichiro Matsumoto2,
- Johannes Reisert2 and
- Tatsuya Yamasoba3
- 1Department of Otolaryngology, Jikei University School of Medicine, Tokyo 105-8461, Japan
- 2Monell Chemical Senses Center, Philadelphia, PA 19104
- 3Department of Otolaryngology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan
- Correspondence should be addressed to Shu Kikuta at sh-kiku{at}m.u-tokyo.ac.jp.
Author contributions
Author contributions: A.K., S.K., I.M., and J.R. designed research; A.K., S.K., and I.M. performed research; A.K. and S.K. analyzed data; A.K., S.K., N.O., H.K., I.M., J.R., and T.Y. wrote the paper.
Disclosures
A.K. and S.K. are inventors in the patents of United States (us 9931380, Medicament for treating olfactory disorder) and Japan (jp 6035524, Dysosmia therapeutic agent) that cover the intellectual property presented in this paper. All other authors declare no competing financial interests.
This work was supported by the Japan Society for Promotion of Science Grant-in-aid for Scientific Research (C) 17K11354 (to S.K.), a Takeda Science Foundation grant (S.K.), and the National Institutes of Health (NIH) Grant R01DC016647 (to J.R.). Immunohistochemistry and confocal microscopy were, in part, performed at the Monell Histology and Cellular Localization Core, which is supported, in part, by the NIH-National Institute on Deafness and Other Communication Disorders Core Grant 1P30DC011735-01 and also from Grant G20OD020296 (infrastructure improvement at the Monell Chemical Senses Center).
Funding
Japan Society for the Promotion of Science (JSPS)
17K11354Takeda Science Foundation
HHS | National Institutes of Health (NIH)
R01DC016647
Other Version
- You are viewing the most recent version of this article.
- previous version (April 27, 2021).
Article usage
In this issue
